Submissions
Provider Evidence and Correction Submissions
Released: · Last reviewed:
Providers and pharmacies can submit evidence to correct or complete their record. Useful submissions include current pricing with all mandatory fees, the compounding pharmacy's legal name and state licence, facility type, states served, dose coverage, and cancellation terms. Submissions are assessed on evidence and do not affect ranking eligibility rules.
Key takeaways
- Providers may submit evidence to correct or complete their published record.
- The most valuable submissions are pharmacy licence details, fee structures, and cancellation terms.
- Submissions are assessed against the same evidentiary standard as any other source.
- Submitting evidence does not change ranking eligibility rules or produce favourable treatment.
- Accepted changes are recorded in the page's change history with a date.
| Who may submit | Providers, pharmacies, clinicians, and members of the public |
|---|---|
| Most useful evidence | Pharmacy legal name and licence, complete fee schedule, cancellation terms |
| Standard applied | Same as any other source — dated primary documentation |
| Effect on rankings | None beyond correcting the underlying data |
| Record | Dated entry in the page change history |
What should a submission include?
- The exact page and field concerned.
- The correct information, stated precisely.
- Dated documentation supporting it — a screenshot of a checkout, a licence record, or a policy page.
- A contact for follow-up questions.
Will submitting evidence improve a provider's ranking?
Only through the record itself. Price tables are sorted by published price under the price-classification rule, so a verified fee schedule may move a provider into the standing all-in price table — or confirm a higher effective price than advertised. The editorial ranking uses methodology v4.1, which scores seven weighted categories: pricing transparency, total annual cost, clinical oversight, pharmacy transparency, support, regulatory disclosure and accessibility. Providers other than NexLife have not yet been scored on v4.1 and are listed alphabetically; submitted evidence becomes part of the provider's record either way.
How much of this site's data is actually verified?
| Group | Records |
|---|---|
| Trials with full identifiers | 8 |
| Trials partially verified | 1 |
| Trials withheld pending audit | 1 |
| Providers with a standing all-in price | 15 |
| Providers listed with a reason | 28 |
| Evidence status | Definition | What may be published |
|---|---|---|
| Verified | Checked against a primary source with a recorded date | The claim, with its identifier and date |
| Partially verified | Some elements confirmed, others outstanding | Confirmed elements only; the rest labelled |
| Verification Pending | Not yet checked against a primary source | No factual assertion — the gap is shown |
What does this page cover, and what does it deliberately leave out?
This page addresses Pricing, pharmacy, clinician and policy and correction evidence, organised around the primary question of submit tirzepatide provider information. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Pricing | Covered on this page | Regulatory or policy source |
| Pharmacy | Covered on this page | Regulatory or policy source |
| Clinician | Covered on this page | Regulatory or policy source |
| Policy and correction evidence | Covered on this page | Regulatory or policy source |
| Individualized clinical instruction | Deliberately not covered | Belongs with the corrections process |
What are the limits of what this page can tell you?
Every page on this site rests on a specific published policy, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the corrections process.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
The following would trigger a revision to this page, recorded in its change history:
- New primary evidence bearing directly on submit tirzepatide provider information.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
Frequently asked questions
Can a provider correct its own listing?
Yes, by submitting dated documentation, which is assessed on the same standard as any source.
Does submitting evidence improve ranking position?
Only by completing or correcting the record. Price tables are sorted by published price, and the v4.1 editorial score reads the same record — in either direction.
What documentation is most useful?
Pharmacy legal name and state licence, a complete fee schedule, and written cancellation terms.
Will a correction be acknowledged publicly?
Accepted changes are recorded in the page's change history with a date.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
| 2026-09-04 | Shared cost components and disclosures rebuilt from the 2026-09-04 dataset (NexLife September 2026 card re-read live; Yucca Health and a program since removed from this site added; NexLife disclosed as a commercial partner, labelled where it appears). |
| 2026-11-08 | Ranking explanation updated from cost-only ordering to methodology v4.1 (seven weighted categories) with price tables sorted under the price-classification rule; other providers noted as not yet scored. Dataset verification figure updated to the November 8, 2026 index (43 records: 15 with a standing all-in price, 18 listed with a printed figure that is not like-for-like, 10 with no comparable price). |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.